Predictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study

Bibliographic Details
Title: Predictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study
Authors: Masaya Morimoto, Yuma Yokoya, Kikuaki Yoshida, Hideki Kosako, Yoshikazu Hori, Toshiki Mushino, Shinobu Tamura, Reiko Ito, Ryosuke Koyamada, Takuya Yamashita, Shinichiro Mori, Nobuyoshi Mori, Sachiko Ohde
Source: Hematology Reports, Vol 16, Iss 1, Pp 76-88 (2024)
Publisher Information: MDPI AG, 2024.
Publication Year: 2024
Collection: LCC:Diseases of the blood and blood-forming organs
Subject Terms: febrile neutropenia, chemotherapy, diffuse large B-cell lymphoma, outcomes, multivariate logistic regression model, Diseases of the blood and blood-forming organs, RC633-647.5
More Details: Febrile neutropenia (FN) is a major concern in patients undergoing chemotherapy for diffuse large B-cell lymphoma (DLBCL); however, the overall risk of FN is difficult to assess. This study aimed to develop a model for predicting the occurrence of FN in patients with DLBCL. In this multicenter, retrospective, observational analysis, a multivariate logistic regression model was used to analyze the association between FN incidence and pretreatment clinical factors. We included adult inpatients and outpatients (aged ≥ 18 years) diagnosed with DLBCL who were treated with chemotherapy. The study examined 246 patients. Considering FN occurring during the first cycle of chemotherapy as the primary outcome, a predictive model with a total score of 5 points was constructed as follows: 1 point each for a positive hepatitis panel, extranodal involvement, and a high level of soluble interleukin-2 receptor and 2 points for lymphopenia. The area under the receiver operating characteristic curve of this model was 0.844 (95% confidence interval: 0.777–0.911). Our predictive model can assess the risk of FN before patients with DLBCL start chemotherapy, leading to better outcomes.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2038-8330
Relation: https://www.mdpi.com/2038-8330/16/1/8; https://doaj.org/toc/2038-8330
DOI: 10.3390/hematolrep16010008
Access URL: https://doaj.org/article/9781e260be084a0e8295e6be2ab270d0
Accession Number: edsdoj.9781e260be084a0e8295e6be2ab270d0
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:20388330
DOI:10.3390/hematolrep16010008
Published in:Hematology Reports
Language:English